paclitaxel has been researched along with altretamine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ozols, RF | 1 |
| Khansur, T; Thigpen, JT; Vance, RB | 1 |
| Chang, C; Imamura, K; Nishimura, H | 1 |
| Anteby, SO; Edelman, DZ; Peretz, T | 1 |
| Alberts, DS; Chapman, JA; Hannigan, EV; Hunter, VJ; Kohler, PC; Liu, PY; Rothenberg, ML; Tiersten, A; Weiner, SA; Weiss, GR; Wilczynski, S | 1 |
| Davy, M; Egorin, M; Ellis, A; Lüftner, D; Olver, I; Park, SH; Webster, L | 1 |
| Gu, M; Ma, D; Wang, C; Wang, S | 1 |
| Herzog, TJ | 1 |
| Alberts, DS; Brady, M; Liu, PY; Markman, M; Monk, BJ; Rothenberg, ML | 1 |
6 review(s) available for paclitaxel and altretamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Role of chemotherapy in the future treatment of ovarian cancer.
Topics: Alkaloids; Altretamine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Female; Humans; Ovarian Neoplasms; Paclitaxel; Remission Induction | 1992 |
Second-line chemotherapy for recurrent carcinoma of the ovary.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1993 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1996 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Recurrence; Tamoxifen | 1996 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
2 trial(s) available for paclitaxel and altretamine
| Article | Year |
|---|---|
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate | 2001 |
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2001 |
6 other study(ies) available for paclitaxel and altretamine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Middle Aged; Mitomycin; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Analysis | 2006 |